智通财经APP获悉,周三,梯瓦制药(TEVA.US)盘前大涨近13%,报23.10美元。梯瓦制药Q3营收为44.8亿美元,市场预期为43.4亿美元;调整后每股收益0.78美元,市场预期为0.68美元。公司预计2025财年全年收入区间为168亿美元至170亿美元,而FactSet的预估为168.3亿美元。公司将2025财年调整后每股收益指引从2.50-2.60美元上调至2.55-2.65美元,分析师预期为2.58美元。
智通财经APP获悉,周三,梯瓦制药(TEVA.US)盘前大涨近13%,报23.10美元。梯瓦制药Q3营收为44.8亿美元,市场预期为43.4亿美元;调整后每股收益0.78美元,市场预期为0.68美元。公司预计2025财年全年收入区间为168亿美元至170亿美元,而FactSet的预估为168.3亿美元。公司将2025财年调整后每股收益指引从2.50-2.60美元上调至2.55-2.65美元,分析师预期为2.58美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.